Tissue biopsies with tumor cell contents that are too low for conventional testing methods can now be rescued due to the ability of MSB’s DEPArray technology* to successfully recover low numbers of tumor cells from these difficult samples. The new FFPE Rescue Application* will provide pathology labs with a validated workflow to identify potentially targetable mutations in more FFPE biopsy samples.
Topics: FFPE, Oncology, DEPArray PLUS
03/12/2019
Technology to Be Introduced at the Molecular Medicine Tri-Conference May Offer Alternative to Invasive Bone Marrow Biopsy for Monitoring Disease Progression
Topics: FFPE, deparray, CELLSEARCH, Liquid biopsy, Precision Medicine, Multiple myeloma, CMMCs
Second World Summit on Cancer Heterogeneity and Precision Medicine Meets in Washington
Topics: FFPE, CTCs, Liquid biopsy, International experts, Menarini International Foundation, Precision Medicine, Cancer Heterogeneity, International conference
Products Optimized for Targeted Resequencing and Exome Sequencing of FFPE Cells
Topics: FFPE, NGS, target sequencing, exome sequencing
Silicon Biosystems, a Bologna (Italy) and San Diego (CA, USA) based biotech company that is part of the pharmaceutical Menarini Group, presented recent findings obtained with its breakthrough state-of-the-art DEPArray™ technology in the characterization of pure tumor cell subpopulations derived from formalin fixed paraffin embedded (FFPE) tissue samples at the European Association of Cancer Research Meeting in Florence (June 20-23).
DEPArray™ technology resolves heterogeneity in solid tumors by digitally sorting 100% pure subpopulations of cells from FFPE samples, thus allowing differential analysis and characterization of tumor vs stromal cell populations resulting in unprecedented data in the subsequent Next Generation Sequencing (NGS) analysis.
Topics: FFPE